In the intention-to-treat (ITT) population, the median Progression-Free Survival (PFS) was 4.1 months in the SIR-Spheres® Y-90 resin microspheres arm vs. 3.7 months in the sorafenib arm (HR: 1.03 [95% CI: 0.85-1.25]; p=0.76).
Reprinted from The Lancet Oncology, Vol. 18, Vilgrain V, Pereira H, Assenat E et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial, Pages 1624-1636., Copyright (2017), with permission from Elsevier.
Vilgrain V et al. Lancet Oncol 2017; 18: 1624–36.